Results 11 to 20 of about 95,020 (310)

Hyperthermic intraperitoneal chemotherapy enhances antitumor effects on ovarian cancer through immune-mediated cancer stem cell targeting

International Journal of Hyperthermia, 2021
Purpose We aimed to determine the effects and possible mechanisms of hyperthermic intraperitoneal chemotherapy (HIPEC) in targeting ovarian cancer stem-like cells (CSCs).
Chao-Chih Wu, Yun-Ting Hsu, Chih-Long Chang   +2 more
doaj   +1 more source

Intraperitoneal Chemotherapy Using Fluorouracil Implants Combined With Radical Resection and Postoperative Adjuvant Chemotherapy for Stage III Gastric Cancer: A Multi-Center, Randomized, Open-Label, Controlled Clinical Study

Frontiers in Oncology, 2021
BackgroundReducing peritoneal recurrence after radical surgery is an important choice to improve the prognosis of patients with advanced gastric cancer.
Yan Xu, Rupeng Zhang, Chunfeng Li, Zhe Sun, Jingyu Deng, Xiaona Wang, Xuewei Ding, Baogui Wang, Qiang Xue, Bin Ke, Hongjie Zhan, Ning Liu, Yong Liu, Xuejun Wang, Han Liang, Yingwei Xue, Huimian Xu   +16 more
doaj   +1 more source

Cytoreduction and HIPEC in the treatment of "unconventional" secondary peritoneal carcinomatosis [PDF]

, 2015
BACKGROUND: Peritoneal metastasis (PM) is considered a terminal and incurable disease. In the last 30 years, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) radically changed the therapeutic approach for these patients ...
Accarpio, Fabio, Biacchi, Daniele, Cardi, Maurizio, DI GIORGIO, Angelo, Mingarelli, Valentina, Musio, Daniela, Sammartino, Paolo, Sibio, Simone, Sollazzo, BIANCA MARIA   +8 more
core   +2 more sources

MODERN STRATEGY IN TREATMENT OF PERITONEAL CARCINOMATOSIS

Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, 2017
Peritoneal carcinomatosis (PC) is a common manifestation of progression in peritoneal and gynecologic malignancies. Current primary strategy in treatment of PC is the concept of regional influence by the way of cytoreductive surgery and intraperitoneal ...
A. A. Zakharenko, D. A. Zaitcev, M. A. Belyaev, A. A. Trushin, O. A. Ten, A. S. Natkha, K. N. Vovin, V. A. Rybalchenko   +7 more
doaj   +1 more source

BEV-IP : perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis [PDF]

, 2015
Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC).
Ceelen, Wim, Liberale, Gabriel, Van Der Speeten, Kurt, Willaert, Wouter   +3 more
core   +2 more sources

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for patients with peritoneal metastases from endometrial cancer [PDF]

, 2017
Background: More information is needed for selection of patients with peritoneal metastases from endometrial cancer (EC) to undergo cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC). Methods: This study analyzed clinical,
Biacchi, Daniele, Christopoulou, Athina, Ciardi, Antonio, Cornali, Tommaso, Efstathiou, Elias, Framarino dei Malatesta, Marialuisa, Kopanakis, Nikolaos, Sammartino, Paolo, Spagnoli, Alessandra, Spiliotis, John   +9 more
core   +1 more source

Effect of intraperitoneal chemotherapy concentration on morbidity and survival

BJS Open, 2020
Background Selected patients with colorectal peritoneal metastases are treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
F. M. K. Elekonawo, W. J. vanEden, W. Y. van derPlas, R. S. G. Ewalds, L. A. W. deJong, A. J. A. Bremers, P. H. J. Hemmer, N. F. M. Kok, S. Kruijff, A. G. J. Aalbers, P. R. deReuver   +10 more
doaj   +1 more source

Prognostic factors influencing infectious complications after cytoreductive surgery and HIPEC. Results from a tertiary referral center [PDF]

, 2019
Background. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) showed promising results in selected patients. High morbidity restrains its wide application.
Carbonari, Ludovica, Cardi, Maurizio, D'Agostino, Claudia, Fonsi, Giovanni Battista, Francesco Di Marzo,, Francesco, Lefoche, LA TORRE, Giuseppe, Sammartino, Paolo, Sibio, Simone   +8 more
core   +1 more source

The next steps in improving the outcomes of advanced ovarian cancer [PDF]

, 2015
Worldwide ovarian cancer affects over 200,000 women per year. Overall survival rates are poor due to two predominate reasons. First, the majority of patients present with advanced disease creating significant difficulty with effecting disease eradication.
Blagden, S, Fotopoulou, C, Gabra, H, Openshaw, MR   +3 more
core   +1 more source

A real-word study: is normothermic intraoperative intraperitoneal chemotherapy impactful as we expect?

Frontiers in Oncology, 2023
BackgroundPatients with gastric cancer have a poor prognosis. Currently, intraperitoneal chemotherapy has been considered a therapeutic option to improve prognosis due to its appealing theoretical rationales.
Mengyao Jin, Wei Cao, Junjie Chen, Maoming Xiong, Guodong Cao, Bo Chen, Bo Chen   +6 more
doaj   +1 more source